Tasosartan

Tasosartan is an angiotensin II receptor antagonist.

Tasosartan
Clinical data
Pregnancy
category
  • N/A
ATC code
Legal status
Legal status
  • Withdrawn
Identifiers
IUPAC name
  • 2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H21N7O
Molar mass411.469 g·mol−1
 NY (what is this?)  (verify)

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]

References
  1. Atkinson AJ, et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 978-0-12-369417-1.
  2. Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm. 57 (13): 1231–41. doi:10.1093/ajhp/57.13.1231. PMID 10902066.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.